BioSpace News Archive

AquiSense Technologies, the world leader in ultraviolet (UV) LED disinfection technology, is happy to announce it has launched the PearlSurface 24G9™, one of the first UV-C LED surface disinfection products designed for health care applications such as reuse of N95 face mask and other PPE.

Today, the Association of Black Cardiologists (ABC) issued frequently asked questions (FAQ Watch) for healthcare providers related to COVID-19.

MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow® (RVF) technology, the newly developed REVEALCOVID-19TM delivers immediate results without the need for any additional equipment such as a reader or a timer.

Athersys, Inc. announced the pricing of its previously announced underwritten public offering of its common stock, par value $0.001 per share, at a price to the public of $2.25 per share, for a total of 22,250,000 shares.

Antibody testing is anticipated to play a critical role in getting people back to work and revitalizing the economy.

Calithera Biosciences, Inc. today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by Calithera. Citigroup is acting as sole book-running m

INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means

Arcturus Therapeutics Holdings Inc. today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject to market conditions

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has completed the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million, and royalties on worldwide sales.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.